Table 3.
Placebo (n = 10) | GM-CSF (n = 10) | p-value | |
---|---|---|---|
IL-2 [pg/mL] | |||
od | 152 (146-271) | 223 (100-481) | 1.000 |
pod1 | 121 (81-172) | 231 (90-354) | 0.181 |
pod2 | 110 (79-216) | 190 (117-414) | 0.073 |
pod3 | 137 (79-199) | 245 (112-467) | 0.138 |
pod4 | 152 (133-207) | 176 (77-505) | 0.699 |
pod5 | 168 (109-223) | 233 (123-415) | 0.366 |
IL-4 [pg/mL] | |||
od | 3.0 (2.0-12.0) | 2.5 (2.0-9.8) | 0.731 |
pod1 | 7.0 (2.0-12.0) | 6.5 (2.0-28.8) | 1.000 |
pod2 | 4.0 (2.0-11.0) | 8.0 (3.5-21.3) | 0.295 |
pod3 | 7.0 (2.0-13.0) | 8.5 (5.0-19.0) | 0.731 |
pod4 | 8.0 (5.3-16.3) | 10.5 (2.0-17.3) | 1.000 |
pod5 | 2.0 (2.0-9.0) | 9.0 (4.3-14.3) | 0.234 |
IL-5 [pg/mL] | |||
od | 6.0 (2.0-26.0) | 23.5 (2.0-33.8) | 0.628 |
pod1 | 9.0 (4.0-65.0) | 19.5 (5.5-69.3) | 0.628 |
pod2 | 5.0 (3.0-31.0) | 11.0 (2.8-29.8) | 0.836 |
pod3 | 11.0 (7.0-20.0) | 26.5 (2.0-59.8) | 0.628 |
pod4 | 11.0 (5.3-28.0) | 15.0 (3.5-38.8) | 1.000 |
pod5 | 7.0 (4.0-17.0) | 14.0 (7.3-48.3) | 0.534 |
IL-10 [pg/mL] | |||
od | 71 (34-91) | 90 (37-130) | 0.731 |
pod1 | 80 (46-136) | 86 (59-131) | 0.731 |
pod2 | 48 (40-104) | 86 (39-148) | 0.628 |
pod3 | 56 (32-72) | 75 (51-125) | 0.445 |
pod4 | 47 (32-115) | 100 (50-112) | 0.394 |
pod5 | 39 (30-67) | 89 (58-143) | 0.101 |
IFN-γ [pg/mL] | |||
od | 757 (275-1,784) | 1,553 (721-3,594) | 0.295 |
pod1 | 296 (95-1,045) | 509 (166-719) | 1.000 |
pod2 | 259 (163-1,084) | 587 (191-913) | 1.000 |
pod3 | 374 (88-1,237) | 765 (491-986) | 0.295 |
pod4 | 318 (230-1,719) | 509 (281-1,462) | 0.589 |
pod5 | 345 (43-1,874) | 724 (289-1,268) | 0.628 |
TNF-α [pg/mL] | |||
od | 378 (107-468) | 571 (220-710) | 0.234 |
pod1 | 110 (18-202) | 167 (82-272) | 0.628 |
pod2 | 70 (39-105) | 162 (31-242) | 0.534 |
pod3 | 116 (87-154) | 167 (117-245) | 0.366 |
pod4 | 152 (78-370) | 116 (78-292) | 0.818 |
pod5 | 209 (29-573) | 193 (155-274) | 1.000 |
Continuous quantities in median (25%-75% percentiles); od, day of surgery before surgery; pod, day after surgery